Bladder Cancer
Diagnosis and Clinical Management
1st Edition
Published on 9. October 2015
Book
Hardback
448 pages
978-1-118-67484-0 (ISBN)
Description
Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult.
In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages with up to date genomic data and targeted therapies. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education.
Full color throughout, and packed with excellent images, each chapter contains concise and didactic practical tips and tricks to enrich the reading experience, in addition to management algorithms and the very latest guidelines from the ASCO, AUA, ESMO and EAU concerning clinical management of bladder cancer.
In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages with up to date genomic data and targeted therapies. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education.
Full color throughout, and packed with excellent images, each chapter contains concise and didactic practical tips and tricks to enrich the reading experience, in addition to management algorithms and the very latest guidelines from the ASCO, AUA, ESMO and EAU concerning clinical management of bladder cancer.
More details
Language
English
Place of publication
Hoboken
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
Product notice
sewn/stitched
Cloth over boards
Dimensions
Height: 246 mm
Width: 191 mm
Thickness: 23 mm
Weight
1089 gr
ISBN-13
978-1-118-67484-0 (9781118674840)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Seth P. Lerner | Mark P. Schoenberg | Cora N. Sternberg
Bladder Cancer
Diagnosis and Clinical Management
E-Book
08/2015
Wiley-Blackwell
€100.99
Available for download
Seth P. Lerner | Mark P. Schoenberg | Cora N. Sternberg
Bladder Cancer
Diagnosis and Clinical Management
E-Book
08/2015
Wiley-Blackwell
€100.99
Available for download
Persons
Seth P. Lerner, Professor of Urology and Beth and Dave Swalm Chair in Urologic Oncology, Baylor College of Medicine, Houston, TX, USA
Mark P. Schoenberg, MD, Professor and University Chair, The Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, Bronx, NY USA
Cora N. Sternberg, Chief, Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy and Adjunct Professor at La Sapienza University in Rome.
Mark P. Schoenberg, MD, Professor and University Chair, The Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, Bronx, NY USA
Cora N. Sternberg, Chief, Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy and Adjunct Professor at La Sapienza University in Rome.
Content
List of contributors vii
Preface xii
Acknowledgments xiii
Part I: Diagnosis and treatment of non-muscle-invasive bladder cancer
1 Pathology 3
Hikmat Al-Ahmadie and Donna E. Hansel
2 Risk stratification of high?]grade Ta CIS and T1 urothelial carcinoma of the bladder 18
Tobias Klatte, Fred Witjes, Gary Steinberg, and Shahrokh F. Shariat
3 Utility of urine biomarkers 26
Derya Tilki and Alexandre R. Zlotta
4 Novel endoscopic techniques for the detection of bladder cancer 39
Ayman Soubra, Joseph C. Liao, and Badrinath Konety
5 Transurethral resection of bladder tumors 51
Jen-Jane Liu and Mark P. Schoenberg
6 Intravesical chemotherapy 64
Levent N. Tuerkeri, M.Guillaume Wientjes, and Jessie L.S. Au
7 Intravesical immunotherapy 76
Nilay M. Gandhi, Laura A. Bertrand, Donald L. Lamm, and Michael A. O'Donnell
8 HGT1 bladder cancer: Diagnosis and treatment 89
J.M. Gaya, J. Palou, and Edward M. Messing
9 What to do when bacillus Calmette-Guerin fails 98
Massimiliano Spaliviero, Guido Dalbagni, and Matthew Nielsen
Part II: T2-4
10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction 111
Robert S. Svatek and Alon Z. Weizer
11 Radical cystectomy: Techniques and outcomes 127
Siamak Daneshmand and Seth P. Lerner
12 Cystectomy in the female patient 144
Ryan Werntz, Georgios Gakis, Theresa Koppie, and Arnulf Stenzl
13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes 156
Kristina Wittig, Kevin Chan, Mark Kawachi, and Timothy G. Wilson
14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials 167
George J.S. Kallingal, Angela B. Smith, Raj S. Pruthi, and Dipen J. Parekh
15 Role of extended lymphadenectomy 176
Eugene K. Cha, George N. Thalmann, and Bernard H. Bochner
16 Management of the urethra in the cystectomy patient 184
Kamal S. Pohar and Norm D. Smith
17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder 190
Scott Delacroix Jr, Nathan Lawrentschuk, and Ashish M. Kamat
Part III: Primary bladder-sparing therapy
18 Radical transurethral resection 201
Eduardo Solsona and Harry W. Herr
19 Partial cystectomy 212
Ahmed Haddad, Yair Lotan, and Arthur I. Sagalowsky
20 Integrating chemotherapy and radiotherapy for bladder cancer 221
Lior Z. Braunstein, William U. Shipley, Nicholas D. James, Andrea B. Apolo, and Jason A. Efstathiou
Part IV: Urinary tract reconstruction
21 Orthotopic neobladder 235
Eila C. Skinner
22 Continent cutaneous diversion 244
Andreas Neisius and Joachim W. Thueroff
23 Non?]continent urinary diversion 258
Michael Rink, Fredrik Liedberg, and Margit Fisch
Part V: Treatment of regionally advanced and metastatic bladder cancer
24 Molecular determinants of chemotherapy response 273
Matthew I. Milowsky, Peter H. O'Donnell, Thomas W. Flaig, and Dan Theodorescu
25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer 284
David I. Quinn and Cora N. Sternberg
26 Adjuvant chemotherapy for invasive bladder cancer 295
Andre P. Fay, Jeffrey J. Leow, and Joaquim Bellmunt
27 Treatment of metastatic bladder cancer 304
Gopa Iyer, Fabio Calabro, and Dean F. Bajorin
28 Treatment of poor risk patients 320
Maria De Santis and Matthew D. Galsky
Part VI: Genomics and the current status of urothelial cancer
29 Molecular events in muscle?]invasive bladder cancer development 329
Jonathan Rosenberg, William Y. Kim, Jaegil Kim, and David J. Kwiatkowski
30 Cancer stem cells and intrinsic subtypes in bladder cancer 342
Keith Syson Chan and David J. McConkey
31 Multi-targeted agents in the treatment of urothelial carcinoma 353
Noah M. Hahn, Colin P.N. Dinney, and Guru Sonpavde
Part VII: Optimizing healthcare delivery
32 Patient navigation and cancer navigator programs 365
Scott M. Gilbert and Michael Porter
33 Impact of health services on compliance and outcomes 375
Heather Honore Goltz, Marc A. Kowalkowski, G. John Chen, and David M. Latini
34 Quality of life and survivorship 384
Nihal E. Mohamed and Cheryl T. Lee
35 Bladder cancer: Healthcare delivery and third party payers 395
Seth A. Strope and John L. Gore
36 Bladder cancer patient advocacy: Creating partnerships to advance patient care research and clinical trials 402
Diane Zipursky Quale and Rick Bangs
Index 409
Preface xii
Acknowledgments xiii
Part I: Diagnosis and treatment of non-muscle-invasive bladder cancer
1 Pathology 3
Hikmat Al-Ahmadie and Donna E. Hansel
2 Risk stratification of high?]grade Ta CIS and T1 urothelial carcinoma of the bladder 18
Tobias Klatte, Fred Witjes, Gary Steinberg, and Shahrokh F. Shariat
3 Utility of urine biomarkers 26
Derya Tilki and Alexandre R. Zlotta
4 Novel endoscopic techniques for the detection of bladder cancer 39
Ayman Soubra, Joseph C. Liao, and Badrinath Konety
5 Transurethral resection of bladder tumors 51
Jen-Jane Liu and Mark P. Schoenberg
6 Intravesical chemotherapy 64
Levent N. Tuerkeri, M.Guillaume Wientjes, and Jessie L.S. Au
7 Intravesical immunotherapy 76
Nilay M. Gandhi, Laura A. Bertrand, Donald L. Lamm, and Michael A. O'Donnell
8 HGT1 bladder cancer: Diagnosis and treatment 89
J.M. Gaya, J. Palou, and Edward M. Messing
9 What to do when bacillus Calmette-Guerin fails 98
Massimiliano Spaliviero, Guido Dalbagni, and Matthew Nielsen
Part II: T2-4
10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction 111
Robert S. Svatek and Alon Z. Weizer
11 Radical cystectomy: Techniques and outcomes 127
Siamak Daneshmand and Seth P. Lerner
12 Cystectomy in the female patient 144
Ryan Werntz, Georgios Gakis, Theresa Koppie, and Arnulf Stenzl
13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes 156
Kristina Wittig, Kevin Chan, Mark Kawachi, and Timothy G. Wilson
14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials 167
George J.S. Kallingal, Angela B. Smith, Raj S. Pruthi, and Dipen J. Parekh
15 Role of extended lymphadenectomy 176
Eugene K. Cha, George N. Thalmann, and Bernard H. Bochner
16 Management of the urethra in the cystectomy patient 184
Kamal S. Pohar and Norm D. Smith
17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder 190
Scott Delacroix Jr, Nathan Lawrentschuk, and Ashish M. Kamat
Part III: Primary bladder-sparing therapy
18 Radical transurethral resection 201
Eduardo Solsona and Harry W. Herr
19 Partial cystectomy 212
Ahmed Haddad, Yair Lotan, and Arthur I. Sagalowsky
20 Integrating chemotherapy and radiotherapy for bladder cancer 221
Lior Z. Braunstein, William U. Shipley, Nicholas D. James, Andrea B. Apolo, and Jason A. Efstathiou
Part IV: Urinary tract reconstruction
21 Orthotopic neobladder 235
Eila C. Skinner
22 Continent cutaneous diversion 244
Andreas Neisius and Joachim W. Thueroff
23 Non?]continent urinary diversion 258
Michael Rink, Fredrik Liedberg, and Margit Fisch
Part V: Treatment of regionally advanced and metastatic bladder cancer
24 Molecular determinants of chemotherapy response 273
Matthew I. Milowsky, Peter H. O'Donnell, Thomas W. Flaig, and Dan Theodorescu
25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer 284
David I. Quinn and Cora N. Sternberg
26 Adjuvant chemotherapy for invasive bladder cancer 295
Andre P. Fay, Jeffrey J. Leow, and Joaquim Bellmunt
27 Treatment of metastatic bladder cancer 304
Gopa Iyer, Fabio Calabro, and Dean F. Bajorin
28 Treatment of poor risk patients 320
Maria De Santis and Matthew D. Galsky
Part VI: Genomics and the current status of urothelial cancer
29 Molecular events in muscle?]invasive bladder cancer development 329
Jonathan Rosenberg, William Y. Kim, Jaegil Kim, and David J. Kwiatkowski
30 Cancer stem cells and intrinsic subtypes in bladder cancer 342
Keith Syson Chan and David J. McConkey
31 Multi-targeted agents in the treatment of urothelial carcinoma 353
Noah M. Hahn, Colin P.N. Dinney, and Guru Sonpavde
Part VII: Optimizing healthcare delivery
32 Patient navigation and cancer navigator programs 365
Scott M. Gilbert and Michael Porter
33 Impact of health services on compliance and outcomes 375
Heather Honore Goltz, Marc A. Kowalkowski, G. John Chen, and David M. Latini
34 Quality of life and survivorship 384
Nihal E. Mohamed and Cheryl T. Lee
35 Bladder cancer: Healthcare delivery and third party payers 395
Seth A. Strope and John L. Gore
36 Bladder cancer patient advocacy: Creating partnerships to advance patient care research and clinical trials 402
Diane Zipursky Quale and Rick Bangs
Index 409